Ask Warren

Daewoong Pharma

069620 · KOSPI · ₩069620 · 대웅제약

₩99,900▲ ₩800 (0.81%)End-of-day · Oct 28, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −29.05%
Market cap
₩1.2T
Enterprise value
₩1.4T
P/E
5.9×
P/B
1.1×
Dividend yield
0.6%
ROE
18.4%
Net margin
12.0%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−49.9% from the high

₩98,400Today: ₩98,400 – ₩101,700₩199,400

Returns

  • 1W−5.2%
  • 1M−7.8%
  • 3M−18.2%
  • 6M−33.2%
  • YTD−42.0%
  • 1Y−29.0%
Volume today
25,048
1.3× the 20-day average
Traded today
₩2.5B
Listed shares
11,586,575
EPS (12 months)
₩16,871
Earnings yield 16.9%
SellBuy
AI research · InitiationDaewoong Pharma: Profits Recovered Since 2024 While the Share Price Fell Roughly 22% Over One YearThe filed numbers show a company with growing revenue, a higher operating margin and strong trailing ROE, valued at low multiples compared with its own recent year-end level and with the much larger listed peers.Read the full report →

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

50Normal
  • BuzzNormalBuzz 50 of 100 (50 is a normal day for this stock).
  • SentimentPositiveNews: Headlines describe a new AI hospital initiative, which reads as a mildly positive development. Community: 0 bullish, 0 bearish posts this week.
  • MomentumWeak-5.9% over the last month; the price is below its 20-day average.
  • News impactLow9 news items and filings in two weeks; 0 rated high impact, 0 medium.

Signals describe activity, not recommendations. Not financial advice.

Leveraged ETF flows

Estimated leveraged-ETF rebalance on Sep 9: sell ₩83M at the close (2.7% of 20-day average trading value)

Aug 11Last 20 trading days (% of average trading value)Sep 9

On its 11 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 4.6% of trading value and pointed the same way 2 of 11 times.

  • 2× KODEX Leverage −₩108M
  • -1× KODEX Inverse ₩8.7M
  • -2× KODEX 200 Futures Inverse 2X ₩5.8M
  • 2× TIGER 200IT Leverage ₩4M
  • 2× TIGER Leverage ₩2.2M

Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.

Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.

Estimate based on ETF size and daily moves; actual trades may differ.

Futures and options

All stock futures →

Futures (2026-11): 99,700

Basis −0.20% · implied rate −4.9%

Open interest 1,288 contracts

Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.

Daewoong Pharma stock overview

Daewoong Pharma (대웅제약, KRX: 069620) is listed on KOSPI, in the Biotech & Pharma sector. Daewoong Pharmaceutical is a Korean company that manufactures and sells pharmaceuticals, listed on the Korea Exchange since 2002. Its shares closed at ₩99,900 on Oct 28, 2026, up 0.81% on the day, giving it a market value of ₩1.2T.

Key facts

Market cap
₩1.2T
Sector
Biotech & Pharma
Latest price change
+0.81%
As of
Oct 28, 2026
Main business
Daewoong Pharmaceutical is a Korean company that manufactures and sells pharmaceuticals, listed on the Korea Exchange since 2002.

Quick answers about Daewoong Pharma

What does Daewoong Pharma do?
Daewoong Pharmaceutical is a Korean company that manufactures and sells pharmaceuticals, listed on the Korea Exchange since 2002. Its main prescription products include the botulinum toxin Nabota, which is largely exported, and drugs such as Ursa, Fexuclue, and Crestor-related lines, with a large share of sales from overseas markets. The company operates manufacturing facilities in Hwaseong and Cheongju, and also develops digital healthcare devices and new drug candidates.
What is the market cap of Daewoong Pharma?
The market capitalisation of Daewoong Pharma was ₩1.2T at the close on Oct 28, 2026.
Who are the largest shareholders of Daewoong Pharma?
According to the latest official filings, the largest reported holders are Daewoong (61.32%, as of Mar 27, 2026); National Pension Service (9.95%, as of Aug 21, 2026); Victory Trivalent International Small-Cap Fund (0.93%, as of Jun 30, 2026).
When is the next earnings report from Daewoong Pharma?
Korean companies rarely announce results dates in advance. Based on when Daewoong Pharma filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Does the National Pension Service own Daewoong Pharma?
Yes. The National Pension Service held 10.30% of Daewoong Pharma shares as of Dec 31, 2025.

Company profile

Daewoong Pharmaceutical is a Korean company that manufactures and sells pharmaceuticals, listed on the Korea Exchange since 2002. Its main prescription products include the botulinum toxin Nabota, which is largely exported, and drugs such as Ursa, Fexuclue, and Crestor-related lines, with a large share of sales from overseas markets. The company operates manufacturing facilities in Hwaseong and Cheongju, and also develops digital healthcare devices and new drug candidates.

Written by AI from the company's latest annual report.

Korean name
대웅제약
Sector
Biotech & Pharma
Themes
Biotech (new drugs)Contract drug manufacturing (CDMO)Obesity drugsAesthetics & botoxPharmaceuticals
CEO
이창재, 박성수
Founded
Oct 2002
Listed
Nov 2002
Listed shares
11,586,575
Fiscal year ends
Month 12
Website
www.daewoong.co.kr

Similar companies

Recent news

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: Daewoong Pharma / 대웅제약 / 069620 / KRX:069620

Source: KRX statistical information